ITM-11 Meets Primary and Secondary End Points in Final Trial Data in Patients with GEP-NETs | Targeted Oncology

Final analysis from the phase 3 COMPETE trial (NCT03049189)¹

revealed that ¹⁷⁷-Lu-edotretide (ITM-11) vs everolimus met its primary and secondary endpoints in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).The final…